Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 144 participants.
Also called NCT01117987
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 144 participants
- Sponsor
- Registry
-
NCT01117987
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01117987. Non-randomized; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
- Acronym
- IMPRES Extn
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Imatinib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01117987- Content hash
8e260a7dc22e53b21308130c125fd645bf6cffa27d86524d96b24d5aca1fc19d